Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
Subscribe To Our Newsletter & Stay Updated
